These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 2144596

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate.
    Boccon-Gibod L, Laudat MH, Dugue MA, Steg A.
    Eur Urol; 1986; 12(6):400-2. PubMed ID: 2949980
    [Abstract] [Full Text] [Related]

  • 4. Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study.
    Di Silverio F, Serio M, D'Eramo G, Sciarra F.
    Eur Urol; 1990; 18 Suppl 3():54-61. PubMed ID: 2151278
    [Abstract] [Full Text] [Related]

  • 5. Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate.
    Schroeder FH, Lock TM, Chadha DR, Debruyne FM, Karthaus HF, de Jong FH, Klijn JG, Matroos AW, de Voogt HJ.
    J Urol; 1987 May; 137(5):912-8. PubMed ID: 2952810
    [Abstract] [Full Text] [Related]

  • 6. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
    Ahmann FR, Citrin DL, deHaan HA, Guinan P, Jordan VC, Kreis W, Scott M, Trump DL.
    J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
    [Abstract] [Full Text] [Related]

  • 7. Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation.
    Kreis W, Ahmann FR, Jordan VC, de Haan H, Scott M.
    Br J Urol; 1988 Oct; 62(4):352-4. PubMed ID: 2973364
    [Abstract] [Full Text] [Related]

  • 8. Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
    Hjertberg H, Varenhorst E, Svensson M, Kågedal B, Nordenskjöld B.
    Acta Oncol; 1988 Oct; 27(4):361-4. PubMed ID: 2974290
    [Abstract] [Full Text] [Related]

  • 9. Advanced prostatic cancer: clinical and hormonal response to flutamide in patients pretreated with LHRH analogue and cyproterone acetate.
    Di Silverio F, Sciarra F, D'Eramo G.
    Eur Urol; 1990 Oct; 18(1):10-5. PubMed ID: 2144819
    [Abstract] [Full Text] [Related]

  • 10. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma.
    Debruyne FM, Denis L, Lunglmayer G, Mahler C, Newling DW, Richards B, Robinson MR, Smith PH, Weil EH, Whelan P.
    J Urol; 1988 Oct; 140(4):775-7. PubMed ID: 2971119
    [Abstract] [Full Text] [Related]

  • 11. The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue.
    Waxman J, Williams G, Sandow J, Hewitt G, Abel P, Farah N, Fleming J, Cox J, O'Donoghue EP, Sikora K.
    Am J Clin Oncol; 1988 Oct; 11 Suppl 2():S152-5. PubMed ID: 2853934
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
    Appu S, Lawrentschuk N, Grills RJ, Neerhut G.
    J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
    [Abstract] [Full Text] [Related]

  • 14. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.
    Bruchovsky N, Goldenberg SL, Akakura K, Rennie PS.
    Cancer; 1993 Sep 01; 72(5):1685-91. PubMed ID: 7688656
    [Abstract] [Full Text] [Related]

  • 15. Suppression of plasma androgens by the antiandrogen flutamide in prostatic cancer patients treated with Zoladex, a GnRH analogue.
    Ayub M, Levell MJ.
    Clin Endocrinol (Oxf); 1990 Mar 01; 32(3):329-39. PubMed ID: 2140542
    [Abstract] [Full Text] [Related]

  • 16. [A 79-year-old man with metastatic prostate cancer, treated with Zoladex, flutamide, calcitonin and Ostac, suffers from frequent troublesome sweating with palpitation and angina pectoris, especially at night. Is there a therapy?].
    Schmeller N.
    Internist (Berl); 1992 Apr 01; 33(4):284. PubMed ID: 1535344
    [No Abstract] [Full Text] [Related]

  • 17. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
    Tomera K, Gleason D, Gittelman M, Moseley W, Zinner N, Murdoch M, Menon M, Campion M, Garnick MB.
    J Urol; 2001 May 01; 165(5):1585-9. PubMed ID: 11342922
    [Abstract] [Full Text] [Related]

  • 18. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O, Kontturi M.
    Scand J Urol Nephrol Suppl; 1988 May 01; 110():109-12. PubMed ID: 2973121
    [Abstract] [Full Text] [Related]

  • 19. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
    Tyrrell CJ, Altwein JE, Klippel F, Varenhorst E, Lunglmayr G, Boccardo F, Holdaway IM, Haefliger JM, Jordaan JP.
    J Urol; 1991 Nov 01; 146(5):1321-6. PubMed ID: 1834864
    [Abstract] [Full Text] [Related]

  • 20. Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer.
    Moffat LE.
    Eur Urol; 1990 Nov 01; 18 Suppl 3():26-7. PubMed ID: 2151272
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.